Toshiba America Medical Systems of Tustin, CA, has received U.S. Food and Drug Administration (FDA) clearance for two new CT clinical applications designed to reduce contrast and radiation dosage and enhance workflow, including a prospective CT scanning protocol.
SureCardio Prospective is designed to reduce patient dose by up to 80% during coronary CT angiography exams through a helical acquisition technique that provides one continuous image instead of multiple images produced by the current step-and-shoot techniques. SureCardio Prospective automatically will detect and adjust to patients with arrhythmia, providing quicker, more conclusive exam results.
Another application, Variable Helical Pitch, is designed to help physicians complete an exam of more than one anatomical region consecutively, without stopping to alter the helical pitch of the exam.
Both applications are available on new Toshiba Aquilion 32- and 64-slice CT systems.
Related Reading
Toshiba reaches Vantage milestone, March 24, 2008
Toshiba appoints new VP of marketing, February 26, 2008
Medicsight, Toshiba ink deal, February 14, 2008
Toshiba adds to cardiac offerings, January 29, 2008
Toshiba gets clearance for Titan MRI scanner, January 28, 2008
Copyright © 2008 AuntMinnie.com
